Biogen Pharmachem Industries (531752) Q4 09/10 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 09/10 earnings summary
26 Oct, 2026Executive summary
FY10 sales were ₹18.815m and net loss narrowed to ₹66,607 from ₹43.334m in FY09.
Directors expected improved turnover despite possible recessionary industry conditions; no dividend was recommended to conserve resources.
Financial highlights
Sales were ₹18.815m versus ₹1,569.093m in FY09; purchases were nil versus ₹1,609.405m.
Administrative and other expenses fell to ₹615,107 from ₹3.507m; loss before and after tax was ₹66,607, with no income-tax or deferred-tax provision.
Total assets rose to ₹441.034m from ₹118.534m, primarily alongside ₹322.5m in preference warrants; net current assets were ₹379.172m.
Outlook and guidance
Directors anticipated significant growth and improved turnover, citing strong Indian-company fundamentals despite possible recessionary industry conditions.
Latest events from Biogen Pharmachem Industries
- Q2 returned to profit, while H1 revenue and net profit declined YoY.531752
Q2 26/27 - Revenue contracted sharply as profits narrowed; outlook centered on commodity trading and wind power.531752Q4 06/07
- FY08 trading contracted sharply, with conflicting reported profit figures and planned wind-power expansion.531752Q4 07/08
- Trading expanded, but a ₹43.33m loss and accumulated-loss risks overshadowed growth plans.531752Q4 08/09
- FY12 loss narrowed, but weak markets constrained revenue and management looked to rebuild turnover.531752Q4 11/12
- Zero operating revenue and a wider FY2012-13 loss contrasted with a sharp rise in investments.531752Q4 12/13
- Nil operating revenue, a ₹1.30 million loss and sharply higher short-term borrowings marked FY14.531752Q4 13/14
- No operations, nil operating revenue, and a ₹1.33m FY15 net loss amid working-capital constraints.531752Q4 14/15
- Nil revenue and working-capital constraints kept operations inactive; FY15/16 net loss was ₹281,764.531752Q4 15/16